A Phase 2 interventional study of AGN-151586 and Placebo in Glabellar Lines, sponsored by Allergan. Completed at 9 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-07-28.
Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the safety and efficacy of AGN-151586 over a range of doses for the treatment of moderate to severe glabellar lines (GL).
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
First submitted before Allergan became part of AbbVie.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period (at least 10 weeks after study intervention).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received AGN-151586-matching placebo, intramuscular (IM) injections in the glabellar complex on Day 1 in Cohort 1.
Drug: Placebo
Participants received AGN-151586 lowest dose, IM injections in the glabellar complex on Day 1.
Drug: AGN-151586
Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 2.
Drug: Placebo
Participants received AGN-151586, IM injections in the glabellar complex on Day 1.
Drug: AGN-151586
Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 3.
Drug: Placebo
Participants received AGN-151586, IM injections in the glabellar complex on Day 1.
Drug: AGN-151586
Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 4.
Drug: Placebo
Participants received AGN-151586, IM injections in the glabellar complex on Day 1.
Drug: AGN-151586
Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 5.
Drug: Placebo
Participants received AGN-151586 highest dose, IM injections in the glabellar complex on Day 1.
Drug: AGN-151586
AGN-151586 solution for injection.
Placebo solution for injection.
Percentage of Participants With ≥ 2-grade Improvement From Baseline on the FWS According to Investigator's Assessment at Any Postintervention Timepoint Through Day 7
Percentage of participants achieving a ≥ 2-grade improvement from baseline on the FWS according to investigator assessments of GL severity at maximum frown at any postintervention timepoint through Day 7 were reported. Investigators' assessments of the severity of GL at rest and maximum frown using the validated FWS was assessed using the 4-grade FWS, where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.
Time frame: Baseline (Day 1) through Day 7
Number of Participants Who Experience One or More Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention or not. TEAEs were defined as events event began on or after the date and time of the study intervention; or the adverse event was present before the date and time of the study intervention, but increased in severity or became serious on or after the date and time of the study intervention.
Time frame: From first dose of study drug until the end of study (up to 42 days)
Number of Participants With Potentially Clinically Significant Laboratory Parameters Post Intervention
Potentially clinically significant post intervention laboratory values included hematology, chemistry, and urinalysis as defined in the SAP.
Time frame: From first dose of study drug until the end of study (up to 42 days)
Number of Participants With Potentially Clinically Significant Vital Signs Post Intervention
Potentially clinically significant post intervention vital sign measurements included systolic and diastolic blood pressure, pulse rate, respiration rate, body temperature as defined in the SAP.
Time frame: From first dose of study drug until the end of study (up to 42 days)
Number of Participants With Potentially Clinically Significant Electrocardiogram Findings Post Intervention
Potentially clinically significant post intervention values in 12-lead ECG recordings included heart rate and measures PR, QRS, QT and QTcF intervals. 12-lead ECG recordings were obtained after the participants have rested for at least 10 minutes in semi-supine or supine position as defined in the SAP. A post-baseline value is considered potentially clinically significant if it meets either the observed-value or the change-from-baseline criteria such as QRS interval observed value: ≥ 150 msec; PR interval observed value: ≥ 250 msec; QTcB observed value: \> 500 msec or change from baseline value: increase of \> 60 msec; QTcF observed value: \> 500 msec or change from baseline value: increase of \> 60 msec.
Time frame: From first dose of study drug until the end of study (up to 42 days)
Number of Participants With Anti-drug Antibodies (ADAs)
Number of participants with positive anti-drug antibodies are reported. Binding and neutralizing anti-bodies are evaluated as anti-drug antibodies. Only participants with positive samples for binding antibodies have been analyzed for presence of neutralizing antibodies.
Time frame: Up to Day 42
| Milestone | Cohort 1: Placebo | Cohort 1: AGN-151586 | Cohort 2: Placebo | Cohort 2: AGN-151586 | Cohort 3: Placebo | Cohort 3: AGN-151586 | Cohort 4: Placebo | Cohort 4: AGN-151586 | Cohort 5: Placebo | Cohort 5: AGN-151586 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 8 | 32 | 12 | 28 | 11 | 27 | 10 | 30 | 9 | 31 |
| Completed | 8 | 31 | 12 | 28 | 10 | 22 | 9 | 30 | 9 | 31 |
| Not completed | 0 | 1 | 0 | 0 | 1 | 5 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Covid-19-related reasons | 0 | 0 | 0 | 0 | 1 | 5 | 0 | 0 | 0 | 0 |
Percentage of participants achieving a ≥ 2-grade improvement from baseline on the FWS according to investigator assessments of GL severity at maximum frown at any postintervention timepoint through Day 7 were reported. Investigators' assessments of the severity of GL at rest and maximum frown using the validated FWS was assessed using the 4-grade FWS, where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.
| percentage of participants | Cohort 1: Placebo | Cohort 1: AGN-151586 | Cohort 2: Placebo | Cohort 2: AGN-151586 | Cohort 3: Placebo | Cohort 3: AGN-151586 | Cohort 4: Placebo | Cohort 4: AGN-151586 | Cohort 5: Placebo | Cohort 5: AGN-151586 |
|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With ≥ 2-grade Improvement From Baseline on the FWS According to Investigator's Assessment at Any Postintervention Timepoint Through Day 7 | 0.0 (NA to NA) | 40.6 (23.7 to 59.4) | 0.0 (NA to NA) | 46.4 (27.5 to 66.1) | 18.2 (2.3 to 51.8) | 70.4 (49.8 to 86.2) | 20.0 (2.5 to 55.6) | 83.3 (65.3 to 94.4) | 11.1 (0.3 to 48.2) | 96.8 (83.3 to 99.9) |
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention or not. TEAEs were defined as events event began on or after the date and time of the study intervention; or the adverse event was present before the date and time of the study intervention, but increased in severity or became serious on or after the date and time of the study intervention.
| Participants | Cohort 1: Placebo | Cohort 1: AGN-151586 | Cohort 2: Placebo | Cohort 2: AGN-151586 | Cohort 3: Placebo | Cohort 3: AGN-151586 | Cohort 4: Placebo | Cohort 4: AGN-151586 | Cohort 5: Placebo | Cohort 5: AGN-151586 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Experience One or More Treatment Emergent Adverse Events (TEAEs) | 3 | 15 | 7 | 10 | 7 | 9 | 3 | 9 | 1 | 12 |
Potentially clinically significant post intervention laboratory values included hematology, chemistry, and urinalysis as defined in the SAP.
| Participants | Cohort 1: Placebo | Cohort 1: AGN-151586 | Cohort 2: Placebo | Cohort 2: AGN-151586 | Cohort 3: Placebo | Cohort 3: AGN-151586 | Cohort 4: Placebo | Cohort 4: AGN-151586 | Cohort 5: Placebo | Cohort 5: AGN-151586 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Potentially Clinically Significant Laboratory Parameters Post Intervention | 0 | 7 | 1 | 5 | 3 | 4 | 0 | 4 | 5 | 8 |
Potentially clinically significant post intervention vital sign measurements included systolic and diastolic blood pressure, pulse rate, respiration rate, body temperature as defined in the SAP.
| Participants | Cohort 1: Placebo | Cohort 1: AGN-151586 | Cohort 2: Placebo | Cohort 2: AGN-151586 | Cohort 3: Placebo | Cohort 3: AGN-151586 | Cohort 4: Placebo | Cohort 4: AGN-151586 | Cohort 5: Placebo | Cohort 5: AGN-151586 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Potentially Clinically Significant Vital Signs Post Intervention | 2 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 0 | 1 |
Potentially clinically significant post intervention values in 12-lead ECG recordings included heart rate and measures PR, QRS, QT and QTcF intervals. 12-lead ECG recordings were obtained after the participants have rested for at least 10 minutes in semi-supine or supine position as defined in the SAP. A post-baseline value is considered potentially clinically significant if it meets either the observed-value or the change-from-baseline criteria such as QRS interval observed value: ≥ 150 msec; PR interval observed value: ≥ 250 msec; QTcB observed value: \> 500 msec or change from baseline value: increase of \> 60 msec; QTcF observed value: \> 500 msec or change from baseline value: increase of \> 60 msec.
| Participants | Cohort 1: Placebo | Cohort 1: AGN-151586 | Cohort 2: Placebo | Cohort 2: AGN-151586 | Cohort 3: Placebo | Cohort 3: AGN-151586 | Cohort 4: Placebo | Cohort 4: AGN-151586 | Cohort 5: Placebo | Cohort 5: AGN-151586 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Potentially Clinically Significant Electrocardiogram Findings Post Intervention | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with positive anti-drug antibodies are reported. Binding and neutralizing anti-bodies are evaluated as anti-drug antibodies. Only participants with positive samples for binding antibodies have been analyzed for presence of neutralizing antibodies.
| Participants | Cohort 1: Placebo | Cohort 1: AGN-151586 | Cohort 2: Placebo | Cohort 2: AGN-151586 | Cohort 3: Placebo | Cohort 3: AGN-151586 | Cohort 4: Placebo | Cohort 4: AGN-151586 | Cohort 5: Placebo | Cohort 5: AGN-151586 |
|---|---|---|---|---|---|---|---|---|---|---|
| Binding Antibodies | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Neutralizing Antibodies | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over All-cause mortality was reported from enrollment to the end of study; median time on follow-up was 42 days for the placebo and AGN-151586 arms, respectively. Treatment-emergent adverse events and serious adverse events were collected from first dose of study drug until 42 days after the last dose of study drug.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Placebo | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Cohort 1: AGN-151586 | 0/32 (0%) | 0/32 (0%) | 15/32 (46.9%) |
| Cohort 2: Placebo | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| Cohort 2: AGN-151586 | 0/28 (0%) | 0/28 (0%) | 10/28 (35.7%) |
| Cohort 3: Placebo | 0/11 (0%) | 0/11 (0%) | 7/11 (63.6%) |
| Cohort 3: AGN-151586 | 0/27 (0%) | 0/27 (0%) | 9/27 (33.3%) |
| Cohort 4: Placebo | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| Cohort 4: AGN-151586 | 0/30 (0%) | 0/30 (0%) | 9/30 (30%) |
| Cohort 5: Placebo | 0/9 (0%) | 0/9 (0%) | 1/9 (11.1%) |
| Cohort 5: AGN-151586 | 0/31 (0%) | 0/31 (0%) | 12/31 (38.7%) |
| Event | Cohort 1: Placebo | Cohort 1: AGN-151586 | Cohort 2: Placebo | Cohort 2: AGN-151586 | Cohort 3: Placebo | Cohort 3: AGN-151586 | Cohort 4: Placebo | Cohort 4: AGN-151586 | Cohort 5: Placebo | Cohort 5: AGN-151586 |
|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/8 | 2/32 | 2/12 | 4/28 | 2/11 | 1/27 | 3/10 | 2/30 | 0/9 | 2/31 |
| Injection site painGeneral disorders | 0/8 | 6/32 | 3/12 | 1/28 | 1/11 | 7/27 | 2/10 | 4/30 | 0/9 | 6/31 |
| EczemaSkin and subcutaneous tissue disorders | 0/8 | 0/32 | 2/12 | 0/28 | 0/11 | 0/27 | 0/10 | 0/30 | 0/9 | 0/31 |
| NasopharyngitisInfections and infestations | 1/8 | 1/32 | 0/12 | 0/28 | 0/11 | 0/27 | 0/10 | 0/30 | 0/9 | 0/31 |
| InfluenzaInfections and infestations | 1/8 | 0/32 | 0/12 | 0/28 | 0/11 | 0/27 | 0/10 | 0/30 | 0/9 | 0/31 |
| Breast indurationReproductive system and breast disorders | 1/8 | 0/32 | 0/12 | 0/28 | 0/11 | 0/27 | 0/10 | 0/30 | 0/9 | 0/31 |
| Injection site pruritusGeneral disorders | 0/8 | 0/32 | 0/12 | 0/28 | 0/11 | 0/27 | 0/10 | 0/30 | 1/9 | 0/31 |
| DiarrhoeaGastrointestinal disorders | 0/8 | 0/32 | 0/12 | 0/28 | 0/11 | 0/27 | 1/10 | 0/30 | 0/9 | 0/31 |
| PyrexiaGeneral disorders | 0/8 | 0/32 | 0/12 | 0/28 | 1/11 | 0/27 | 0/10 | 0/30 | 0/9 | 0/31 |
| DizzinessNervous system disorders | 0/8 | 0/32 | 1/12 | 0/28 | 1/11 | 1/27 | 0/10 | 0/30 | 0/9 | 0/31 |
Modified intent-to-treat (mITT) population included all randomized participants who received the study intervention and who had at least one postintervention investigator-rated facial wrinkle scale with photonumeric guide (FWS) measurement at maximum frown.
| Age, Continuous(years) | Cohort 1: Placebo | Cohort 1: AGN-151586 | Cohort 2: Placebo | Cohort 2: AGN-151586 | Cohort 3: Placebo | Cohort 3: AGN-151586 | Cohort 4: Placebo | Cohort 4: AGN-151586 | Cohort 5: Placebo | Cohort 5: AGN-151586 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 49.9 ± 6.24 | 52.8 ± 8.85 | 47.0 ± 9.39 | 50.9 ± 10.10 | 50.1 ± 10.63 | 47.5 ± 10.53 | 39.0 ± 7.94 | 45.3 ± 8.06 | 51.1 ± 11.37 | 46.4 ± 10.30 | 48.3 ± 9.91 |
| Sex: Female, Male(Participants) | Cohort 1: Placebo | Cohort 1: AGN-151586 | Cohort 2: Placebo | Cohort 2: AGN-151586 | Cohort 3: Placebo | Cohort 3: AGN-151586 | Cohort 4: Placebo | Cohort 4: AGN-151586 | Cohort 5: Placebo | Cohort 5: AGN-151586 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 7 | 29 | 12 | 25 | 11 | 24 | 9 | 26 | 9 | 30 | 182 |
| Male | 1 | 3 | 0 | 3 | 0 | 3 | 1 | 4 | 0 | 1 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Placebo | Cohort 1: AGN-151586 | Cohort 2: Placebo | Cohort 2: AGN-151586 | Cohort 3: Placebo | Cohort 3: AGN-151586 | Cohort 4: Placebo | Cohort 4: AGN-151586 | Cohort 5: Placebo | Cohort 5: AGN-151586 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 9 | 3 | 4 | 4 | 8 | 3 | 12 | 0 | 7 | 52 |
| Not Hispanic or Latino | 6 | 23 | 9 | 24 | 7 | 19 | 7 | 18 | 9 | 24 | 146 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1: Placebo | Cohort 1: AGN-151586 | Cohort 2: Placebo | Cohort 2: AGN-151586 | Cohort 3: Placebo | Cohort 3: AGN-151586 | Cohort 4: Placebo | Cohort 4: AGN-151586 | Cohort 5: Placebo | Cohort 5: AGN-151586 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 3 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 4 |
| Black or African American | 1 | 2 | 0 | 2 | 0 | 0 | 0 | 2 | 1 | 2 | 10 |
| White | 7 | 27 | 10 | 24 | 10 | 26 | 10 | 28 | 7 | 26 | 175 |
| More than one race | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Sep 2019 to primary completion in Sep 2020, 11 months.
Results were first posted in Jul 2023, 2 years 10 months after primary completion. A results delay was requested in Jul 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: trenibotulinumtoxinE